# A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity

Study · id `cardio:ct-nct07919405` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07919405](<https://clinicaltrials.gov/study/NCT07919405>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07919405

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1408 participants.

## Technical summary

Registry record NCT07919405. Randomized; quadruple masking; primary purpose treatment. Start 2026-11-11 (anticipated); primary completion 2028-06-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1408 participants (planned count; ClinicalTrials.gov record NCT07919405, source copy `cardio:ctgov-nct07919405-2026-11-05`, retrieved 2026-11-18)
- Planned start: 2026-11-11 (anticipated) (ClinicalTrials.gov record NCT07919405, source copy `cardio:ctgov-nct07919405-2026-11-05`, retrieved 2026-11-18)
- Primary completion: 2028-06-01 (anticipated) (ClinicalTrials.gov record NCT07919405, source copy `cardio:ctgov-nct07919405-2026-11-05`, retrieved 2026-11-18)
- Completion: 2028-07-13 (anticipated) (ClinicalTrials.gov record NCT07919405, source copy `cardio:ctgov-nct07919405-2026-11-05`, retrieved 2026-11-18)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Bulgaria; Canada; Denmark; Germany; Hungary; Italy; Japan; Netherlands; Poland; Puerto Rico; South Africa; South Korea; Spain; United Kingdom (ClinicalTrials.gov record NCT07919405, source copy `cardio:ctgov-nct07919405-2026-11-05`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07919405-2026-11-05`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
- Acronym: REDEFINE
- Condition: Hypertension
- Condition: Obesity
- Intervention (Drug): CagriSema
- Intervention (Drug): Semaglutide
- Intervention (Drug): Cagrilintide
- Intervention (Drug): Placebo
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: ac7d67baf47a9c11c377eb0a6bfad2a29bc20b84f28160e2eab672046b4c1e1e
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
